Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.08−0.66 (-3.52%)
Close on Nov 16, 2026Market cap $2.89BP/E –Yield –
Denali Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Denali Therapeutics's profit margin for the twelve months ending Jun 30, 2024 was -33121.9%. For fiscal 2023 it was -43.9%, against -300.6% the year before. The highest annual figure on record is 21.2% in fiscal 2020.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -43.9% | +256.6 |
| FY2022 | Dec 31, 2022 | -300.6% | +296.6 |
| FY2021 | Dec 31, 2021 | -597.2% | −618.3 |
| FY2020 | Dec 31, 2020 | 21.2% | +761.9 |
| FY2019 | Dec 31, 2019 | -740.7% | −712.7 |
| FY2018 | Dec 31, 2018 | -28.1% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -3539.2% | −2579.6 |
| Q3 FY2023 | Sep 30, 2023 | -7841.6% | −4939.1 |
| Q2 FY2023 | Jun 30, 2023 | 62.3% | +174.4 |
| Q1 FY2023 | Mar 31, 2023 | -312.4% | −157.6 |
| Q4 FY2022 | Dec 31, 2022 | -959.6% | −358.2 |
| Q3 FY2022 | Sep 30, 2022 | -2902.5% | −1301.9 |
| Q2 FY2022 | Jun 30, 2022 | -112.0% | +152.5 |
| Q1 FY2022 | Mar 31, 2022 | -154.8% | +729.3 |
| Q4 FY2021 | Dec 31, 2021 | -601.4% | −678.7 |
| Q3 FY2021 | Sep 30, 2021 | -1600.5% | −980.6 |
| Q2 FY2021 | Jun 30, 2021 | -264.6% | +740.3 |
| Q1 FY2021 | Mar 31, 2021 | -884.0% | +691.0 |
| Q4 FY2020 | Dec 31, 2020 | 77.3% | +1233.7 |
| Q3 FY2020 | Sep 30, 2020 | -619.9% | −279.9 |
| Q2 FY2020 | Jun 30, 2020 | -1004.9% | +385.0 |
| Q1 FY2020 | Mar 31, 2020 | -1575.0% | −647.7 |
| Q4 FY2019 | Dec 31, 2019 | -1156.4% | −1218.0 |
| Q3 FY2019 | Sep 30, 2019 | -340.0% | +2619.9 |
| Q2 FY2019 | Jun 30, 2019 | -1390.0% | +1930.7 |
| Q1 FY2019 | Mar 31, 2019 | -927.3% | +2766.6 |
| Q4 FY2018 | Dec 31, 2018 | 61.7% | – |
| Q3 FY2018 | Sep 30, 2018 | -2959.9% | – |
| Q2 FY2018 | Jun 30, 2018 | -3320.6% | – |
| Q1 FY2018 | Mar 31, 2018 | -3693.9% | – |
See a number that looks wrong?